Evaluation of nonspreading Rift Valley fever virus as a vaccine vector using influenza virus hemagglutinin as a model antigen

N. Oreshkova, L.A.H.M. Cornelissen, C.A.M. de Haan, R.J.M. Moormann, J.A. Kortekaas

Research output: Contribution to journalArticleAcademicpeer-review

9 Citations (Scopus)

Abstract

Virus replicon particles are capable of infection, genome replication and gene expression, but are unable to produce progeny virions, rendering their use inherently safe. By virtue of this unique combination of features, replicon particles hold great promise for vaccine applications. We previously developed replicon particles of Rift Valley fever virus (RVFV) and demonstrated their high efficacy as a RVFV vaccine in the natural target species. We have now investigated the feasibility of using this nonspreading RVFV (NSR) as a vaccine vector using influenza virus hemagglutinin as a model antigen. NSR particles were designed to express either the full-length hemagglutinin of influenza A virus H1N1 (NSR-HA) or the respective soluble ectodomain (NSR-sHA). The efficacies of the two NSR vector vaccines, applied via either the intramuscular or the intranasal route, were evaluated. A single vaccination with NSR-HA protected all mice from a lethal challenge dose, while vaccination with NSR-sHA was not protective. Interestingly, whereas intramuscular vaccination elicited superior systemic immune responses, intranasal vaccination provided optimal clinical protection.
Original languageEnglish
Pages (from-to)5323-5329
JournalVaccine
Volume32
Issue number41
DOIs
Publication statusPublished - 2014

Keywords

  • rna recombination
  • rhesus macaques
  • in-vivo
  • protein
  • replication
  • epitope
  • nss

Fingerprint Dive into the research topics of 'Evaluation of nonspreading Rift Valley fever virus as a vaccine vector using influenza virus hemagglutinin as a model antigen'. Together they form a unique fingerprint.

Cite this